微信直播

AME新书《早期肺癌:手术 vs 立体定向放疗》招募译者

Published at: 2015年第1卷第S1期

关键词:

肺癌,通常被“简单粗暴”地分为可手术的早期肺癌和不可手术的晚期肺癌。不可手术的晚期肺癌一般交由肿瘤科医生,通过放化疗等方式,减轻患者的症状乃至治愈患者;而可手术早期肺癌,不言而喻,则是外科医生的管辖范围,大家都相信对于早期肺癌,手术切除是最直接利落的解决方法。然而这一种认知和默契在一定程度上似乎就要被打破了。

正在试图打破这一局面的,是几年内迅速引起业内人士热议、连大众都极为关注的立体定向放疗SBRT. 而这一次,放疗医生们将目标转移至可手术的早期肺癌,并在积累一定经验和试验后,高调宣布立体定向放疗 SBRT 是可手术早期肺癌患者等同于手术的另一种选择,同时由于放疗避免了手术创伤,似乎成了一种更有利的选择。到底孰优孰劣?小编说了当然不算,那谁说了算?

唇枪舌战间,AME 王牌学术委员——外科医生沈亚星医生和肿瘤放疗科周支瑞博士——已召集邀请了73位包括美国、德国、加拿大、西班牙等多国胸外科和放疗方面的权威专家(图1),共同撰写著书 Surgery VS Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer(图2),从其发展历史、现有的证据、临床经验、争议所在,再到未来的方向,深度解读在早期肺癌中手术和立体定向放疗的PK,更提出令人发省的顾虑和鼓励。

图1. Surgery VS Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer 作者国籍分布

图2. Surgery VS Stereotactic Body Radiation Therapy for Early-Stage Lung Cancer 封面,水彩大师徐志晶老师作品

跟往常一样,AME将同步发行本书的其中文版《早期肺癌:手术 vs 立体定向放疗》,现诚邀国内外优秀医学工作者作为译者参与本书的出版,撰写书评分享给同行等。待浏览完书目以及作者列表,或许你会讶异本书有点过于强大的国际阵容,小编决定剧透一丢丢。

外科大师Diego Gonzalez-Rivas (西班牙), Alan D. L. Sihoe (中国香港), Gaetano Rocco (意大利), 方文涛(中国),Thomas A. D’Amico (美国);著名的放疗医生包括 Joe Y Chang(美国), Suresh Senan(荷兰), Johannes Roesch(瑞士), Andrea Bezjak(加拿大), Katrina Woodford(澳大利亚),10位大拿纷纷为本书作序,以表支持。以收到的序言来看,仍有偶尔的刀光剑影,但明显更多的是收起兵刃,心平气和地探讨、肯定甚至鼓励双方,携手为更好服务于患者而努力。是否都感动了呢,赶紧浏览下方的认领方法,加入我们吧!

认领方法:

方法一:点击阅读原文认领(欢迎关注AME科研时间amegroups公众号)。

方法二:复制AME认领系统链接:(推荐)

http://rl.amegroups.com/User/Assignment?Type=0001&HidTaskNO=SBRT_001

  • Step 1. 尚未注册账号的认领者需要【注册】并激活账号:复制链接(http://rl.amegroups.com)

  • Step 2. 用户登录并进入【翻译】板块,选择【NO.】:如SBRT_001, 点击认领即可;或查询可认领文章,从【待认领】文章中选择认领。

  • Step 3. 认领成功后,请选择【下载】来获取原文,同时请务必查看【要求】,按要求翻译文章。有问题请联系下列邮箱:kysj@amepc.org 。每人最多认领两篇。

认领截止日期:本次认领长期有效,直至认领完毕。

认领成功后,请在认领成功后的三周内将翻译稿及个人简介发送到 kysj@amepc.org。

 

凡翻译质量通过审核的译者,可获得:

1.每翻译一篇文章,即可获得价值200元人民币的科研时间积分(200快币)以及免费登录视频数据库ASVIDE,观看手术视频(积分限免)。

2.译者署名。

3.获赠本书中英文版各一本。

 

文章目录

编号

文章题目

1

Stereotactic ablative radiotherapy for stage I NSCLC: Recent advances and controversies

2

What is the current status of Stereotactic body radiotherapy for stage I non-small cell lung cancer?

3

Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer

4

Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy

5

Stereotactic ablative radiotherapy: aim for a cure of cancer

6

Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung

7

Is staging mediastinoscopy necessary before stereotactic body radiotherapy for inoperable early stage lung cancer?

8

A millimeter miss is as good as a thousand miles: The role of accurate target localization in lung stereotactic body radiation therapy

9

The factors affecting local tumor control after stereotactic body radiotherapy for non-small cell lung cancer

10

Are three doses of stereotactic ablative radiotherapy (SABR) more effective than 30 doses of conventional radiotherapy?

11

Stereotactic ablative radiotherapy for stage I NSCLC: Successes and existing challenges

12

Stereotactic ablative radiotherapy for early stage non-small cell lung cancer: a word of caution

13

Improved survival with stereotactic ablative radiotherapy (SABR) over lobectomy for early stage non-small cell lung cancer (NSCLC): addressing the fallout of disruptive randomized data

14

Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard

15

Stereotactic ablative radiotherapy and surgery: two gold standards for early-stage non-small cell lung cancer?

16

A pooled analysis of stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small cell lung cancer: is failure to recruit patients into randomized trials also an answer to the research question?

17

The radiobiological targets of SBRT: tumor cells or endothelial cells?

18

Stereotactic ablative body radiotherapy (SABR): an alternative to surgery in stage I-II non-small-cell cancer of the lung?

19

Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

20

Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

21

Rebuttal from Ms Woodford and Dr Senthi

22

Rebuttal from Dr Nestle and Dr Belderbos

23

Surgery or stereotactic ablative radiation therapy: how will be treated operable patients with early stage not small cell lung cancer in the next future?

24

Stereotactic body radiation therapy (SBRT) for non-small cell lung cancer (NSCLC): current concepts and future directions

25

Stereotactic ablative radiotherapy (SABR) for lung cancer: What does the future hold?

comments powered by Disqus

附件